Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Ginecol Obstet Mex ; 66: 309-15, 1998 Aug.
Artículo en Español | MEDLINE | ID: mdl-9745190

RESUMEN

Pelvic inflammatory disease (PID) is one of the most severe complications of sexually transmitted disease (STD). It can be due to the ascending of normal endogenous microorganisms of the female genital tract or the infection by microorganisms related to STD as Chlamydia trachomatis and Neisseria gonorrhoeae. PID leads to serious gynecoobstetric consequences as infertility and ectopic pregnancy. Clinicians face the problem of knowing the ethiology of PID in order to treat appropriatly patients with this clinical diagnosis. So that, this work pretends to establish what kind of microorganisms are implicated in PID. A proper isolation and identification of microorganisms achieved by culture of lower genital tract samples from endocervix, endometrium and peritoneal fluid, leading to a betther, specific and proper treatment of this disease.


Asunto(s)
Enfermedad Inflamatoria Pélvica/microbiología , Complicaciones del Embarazo/microbiología , Antibacterianos/uso terapéutico , Infecciones por Chlamydia/tratamiento farmacológico , Femenino , Gonorrea/tratamiento farmacológico , Gonorrea/microbiología , Humanos , Enfermedad Inflamatoria Pélvica/terapia , Embarazo , Índice de Severidad de la Enfermedad , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Infecciones Estreptocócicas/tratamiento farmacológico
3.
Ginecol Obstet Mex ; 62: 226-34, 1994 Aug.
Artículo en Español | MEDLINE | ID: mdl-7959144

RESUMEN

Efficiency and security clindamycin vaginal cream (2%) were compared to oral metronidazole's for the treatment of 184 women with symptomatic bacterial vaginosis in a multicentric, randomized, double-blind, controlled study. The treatment was of 7 days duration, using placebo capsules for the clindamycin group and placebo cream for the metronidazole group. Patients were observed during a follow up (4-13 and 20-43 days after completion of therapy). Global results of this treatment indicated that clindamycin vaginal cream offers a similar efficiency than oral metronidazole. Improvement or total healing was 87% for clindamycin and 79% for metronidazole, with no significant differences (p > 0.22). No relapses were observed in the clindamycin group, and 7% in the metronidazole group. The clindamycin group had a failure rate of 3% compared to 15% in the oral metronidazole group. Both drugs were well tolerated. Side effects more frequently reported were vulvovaginal irritation and cervicitis/vaginitis. The only side effect that could have been classified as serious was a generalized rash in a patient receiving metronidazole. It was concluded that clindamycin vaginal cream (2%) is an efficient and secure alternative to oral metronidazole for the treatment of bacterial vaginosis being the elective therapy for pregnant women in their first gestational trimester.


Asunto(s)
Clindamicina/uso terapéutico , Metronidazol/uso terapéutico , Cremas, Espumas y Geles Vaginales , Vaginosis Bacteriana/tratamiento farmacológico , Administración Oral , Adolescente , Adulto , Clindamicina/administración & dosificación , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Metronidazol/administración & dosificación , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA